Initial enthusiasm was tempered by the disappointing results of large, randomized phase III trials, most notably the EVOLVE-1 study, where the mTOR inhibitor everolimus failed to improve overall survival in patients with advanced HCC who had progressed on sorafenib 105. Here, MTOR is linked to hepatocellular carcinoma.